APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.
Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.
APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
Location: Austria, Vienna
Member count: 11-50
Founded date: 2003
Investors 1
Date | Name | Website |
- | Medison Ve... | medisonven... |
Mentions in press and media 4
Date | Title | Description | Category | Author | Source |
12.10.2021 | APEIRON Bi... | DGAP-News: APEIRON Biologics A... | - | - | marketscre... |
06.07.2021 | APEIRON Bi... | DGAP-News: APEIRON Biologics A... | - | - | marketscre... |
01.06.2021 | APEIRON Bi... | DGAP-News: APEIRON Biologics A... | - | - | marketscre... |
19.05.2021 | APEIRON Bi... | DGAP-News: APEIRON Biologics A... | - | - | marketscre... |